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Purpose of review:   
Optimal treatment of brain metastases has been limited to local treatment with few 
systemic options.  Increasing use of targeted therapies, chemotherapy and 
immunotherapy and combination of local and systemic treatments resulted in 
plethora of publications.  We review the existing evidence for individual treatments 
and new evidence for the integration of systemic and combination of local 
treatments. 
  
Recent findings:   
Encouraging efficacy of systemic therapies supports combination of systemic and 
local treatment albeit without randomised trials.  Efficacy particularly of targeted 
agents provides an opportunity to delay local treatments including radiosurgery and 
whole brain radiotherapy.  Randomised trials testing the integration of surgery, 
radiotherapy and radiosurgery are reviewed with emphasis on patient relevant 
endpoints to guide the clinician in the choice and sequence of treatments and 
integrating systemic and local therapies.  
  
Summary:  
There is increasing tendency to use focused radiation for single and oligometastases 
with or without surgery and decline in whole brain radiotherapy which is limited to 
multiple metastases in tumours without effective systemic options. Systemic 
therapies have promising intracranial efficacy and the sequence and combination 
with localised radiation is awaiting trials.   Changes in practice with a move to 
primary systemic treatment for brain metastases without radiation, should be 









The incidence of brain metastases and associated morbidity and mortality is rising 
most likely as a result of more frequent brain imaging and the use of more effective 
local and systemic therapies.  Up to 30% of patients with tumours such as melanoma 
and lung adenocarcinoma have intracranial metastases at the time of diagnosis (1) 
and many more will develop intracranial disease during the course of their disease; 
up to 50% of patients with Her-2 positive breast cancer develop brain metastases 
(2).  
Metastatic disease in the brain had been considered within a “sanctuary site” and 
treatment approaches have been directed specifically at the brain. With greater 
understanding of the natural history and response to treatment, management 
policies have become more complex and varied often combining treatment for brain 
and systemic disease, the use of surveillance in asymptomatic patients and the use 
of more localised treatment approaches with surgery and focused radiation. We 
discuss the current evidence which underpins the changing practice particularly 
focusing on the integration of the various treatments. With increasing interest in new 
approaches to tackle intracranial metastatic disease, treatments considered 
appropriate in 2020 may also become outdated. However any newly accepted 
treatment policies should be guided by high level evidence rather than enthusiasm 
for novelty and technological advances of uncertain clinical importance, and should 
be demonstrated to be of real benefit to patients in terms of survival and quality of 
life, avoiding intermediate and surrogate endpoints of little or no relevance to 
patients. 
 
Changing role of whole brain radiotherapy (WBRT) 
The role of WBRT, standard “fit all” treatment of previous decades, has been 
challenged by the QUARTZ trial which compared WBRT with “optimal supportive 
care” (OSC) including corticosteroids, in 538 patients with poor prognosis non-small 
cell lung cancer (NSCLC) and brain metastases. With an overall median survival of 
only 2 months (i.e. the worst prognosis patients) it showed no survival or quality of 
life benefit for WBRT. While it has been interpreted by some as showing that WBRT 
has no role in patients with NSCLC and brain metastases, a potential survival benefit 
was seen in younger patients and those with a more favourable prognostic profile 
(3). 
WBRT therefore currently remains the treatment of choice in patients with NSCLC 
and other primary tumours with more favourable prognosis and disseminated 
malignancy not responsive to systemic treatment and not amenable to local 
therapies (radiosurgery or surgery). However, WBRT should be carefully considered 
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for each patient as achieving intracranial disease control may be associated with 
worse cognitive decline than seen in patients receiving local therapies (4, 5). 
In patients with multiple lesions localised to specific parts of the brain partial brain 
irradiation (as fractionated conformal radiotherapy) to either palliative or radical 
doses dependent on the status of systemic disease provides an alternative to 
WBRT. Partial brain radiotherapy has not been subject to randomised studies 
although it carries a significant benefit in terms of avoiding radiation to large parts of 
apparently uninvolved normal brain avoiding possible functional consequences of 
irradiation. The use of Memantine to reduce the cognitive decline ascribed to WBRT 
failed to show a clinically significant improvement in a randomised study (6, 7).  
 
Stereotactic radiosurgery (SRS) 
SRS allows for highly focussed radiation to small targets. It can be delivered using a 
conventional linear accelerator, a small linear accelerator mounted on a robotic arm 
(Cyberknife™) or a multiheaded cobalt unit (Gamma Knife™). While there are 
technical differences in the detail of treatment planning and treatment delivery there 
are no known significant differences in the outcome of treatment using any of the 
equipment and treatment techniques. However the use of focal RT needs to be 
supported by a significant infrastructure and expertise in high precision treatment 
delivery. 
The demonstration that SRS in addition to WBRT prolongs survival in patients with 
single brain metastases (8) has led to increasing use of SRS in patients with 
oligometastases and multiple brain metastases as an alternative to wide field 
irradiation.  In patients with multiple brain metastases treated with radiation alone 
(i.e. without previous surgery) SRS alone has not been formally compared to WBRT.  
In patients with oligometastases neuro-cognitive function decline is greater following 
WBRT than SRS alone (9) though this is not yet demonstrated for a larger number of 
lesions where the temptation is to treat each lesion as an individual metastasis with 
SRS (10).  
A technically simpler alternative to avoid WBRT is a technique of single isocentre 
volumetric modulated arc therapy (VMAT) using a linear accelerator. With either of 
the techniques, which are manpower and equipment use intensive, a significant dose 
is delivered to normal unaffected brain although lower than WBRT dose and the 
potential advantage in sparing cognitive function remains to be demonstrated. In the 
absence of a survival benefit for the more localised technique of radiation, the most 
important endpoint for patients with single or multiple brain metastases is 
improvement in symptoms and maintenance of quality of life (QoL) rather than 
endpoints such as local or distant failure potentially amenable to further treatment 
providing this is appropriate in the context of the overall disease.  Randomised 
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studies focusing on QoL and functional endpoints in addition to survival are needed 
to help with the choice of treatment for individual patients.  
Most randomised studies evaluating technology tend to include patients with a range 
of tumour types and are not generally single disease specific. Further studies in 
different tumours and molecular subtypes particularly in patients with favourable 
prognosis may define optimal use and timing of SRS. Such refinements are likely to 
be driven by the availability and efficacy of systemic treatments.   
SRS is not without risk and can cause radiation necrosis, cognitive decline and 
vascular sequelae. The risk of radiation necrosis is in the region of 10-20%, is dose 
and volume dependent and is increased by previous cranial surgery and radiation. 
Due to the higher risk of radiation necrosis treating large lesions to high single doses 
the current trend is to use high dose fractionated/hypofractionated stereotactic 
radiotherapy with similar efficacy and lesser toxicity (11) although this has not been 
subject to randomised trials. 
 
Surgery 
With modern surgical techniques, resection is considered the treatment of choice for 
patients with large and cystic lesions with a significant mass effect who are likely to 
benefit from surgical debulking (12) where removal of a tumour mass is likely to 
provide rapid symptomatic relief. Surgical resection is considered suitable for up to 3 
lesions, although surgery for multiple metastases has not been subject to 
randomised trials. Surgery in combination with WBRT is associated with survival 
benefit in patients with solitary metastases compared to WBRT alone (13) although 
this was not clearly demonstrated in larger randomised studies (14, 15).  While not 
subject to head-to-head comparison in randomised trials, it is likely that both SRS 
and surgery are equivalent in achieving local disease control where surgery is 
preferred for accessible lesions with a significant mass effect. 
 
Combination of surgery, radiosurgery and radiotherapy 
Due to a significant risk of distant intracranial disease progression following 
treatment of solitary brain metastases with surgery or SRS the policy had been to 
offer adjuvant whole brain radiotherapy following local treatment. Three randomised 
trials of WBRT (16-18) while demonstrating improved intracranial disease control 
have shown no survival benefit, no prolongation of functional independence 
(measured as remaining with good performance status) (17) with detriment in terms 
of cognitive function. There is currently therefore no clear justification for the use of 
WBRT following surgery or radiosurgery for solitary or oligometastases. 
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Due to a risk of recurrence at the site of tumour resection, adjuvant SRS to the 
resection cavity following tumour excision was examined in randomised trials. 
Although local and distant brain control were worse with adjuvant SRS than WBRT 
(19), the overall survival was no different and WBRT was associated with worse 
cognitive decline.  A single-centre randomised trial of SRS to the resection cavity 
following surgery compared with surgery alone (20) demonstrated high local control 
rates following SRS similar to those achieved following WBRT (19).  However 
adjuvant SRS was not associated with a survival benefit and 4% of patients receiving 
SRS developed radiation necrosis. While SRS has lesser adverse effect than WBRT 
it is less effective in achieving disease control in the brain outside the treated site so 
that same proportion of SRS and surveillance patients require subsequent treatment 
with WBRT (19, 20). Post-operative radiotherapy was compared in a randomised 
trial to surveillance and salvage SRS (similar to a comparison of WBRT and SRS 
where only proportion of patients receive SRS). The study showed no survival 
difference and no difference in cognitive function measured with Mini-Mental Status 
Examination (MMSE) though this is a poorly discriminatory test (21). Following 
surveillance and salvage SRS proportion of surviving patients received WBRT within 
6 months of surgery. The studies suggest that it is reasonable to defer adjuvant 
treatment and offer SRS or WBRT depending on the pattern of brain recurrence.  As 
there is no survival advantage with either WBRT or SRS postoperatively, avoidance 
of toxicity is an important factor on which to decide to offer adjuvant treatment.  The 
reduction of cognitive decline with SRS compared to WBRT is clinically important 
particularly for patients with high risk of progression following surgery.  
SRS to the resection cavity is considered by some as the “standard of care” (22, 23) 
based on local control at the resection site and little risk of toxicity and therefore has 
been widely adopted, although the absolute advantage remains of uncertain 
relevance for the patient, and may ultimately vary with other factors such as systemic 
control and systemic treatment options as well as the risk of local and overall 
intracranial recurrence.  Randomised-controlled, stratified studies comparing 
surveillance with post-operative SRS would help answer this question with relevant 
primary endpoints such as retaining functional status and independence, freedom 
from the need for further treatment and QoL. 
Delivering SRS preoperatively may confer some advantages to post-operative 
treatment, including the ability to treat the actual rather than imagined site of disease 
with a potential lower risk of necrosis.  SRS may also reduce the viability of residual 
tumour cells at the tumour margin and theoretically may reduce intraoperative 
tumour spillage and therefore the risk of leptomeningeal disease as suggested in 
retrospective studies (24). A randomised trial of preoperative versus postoperative 
SRS is currently underway as well as a further trial assessing molecular changes in 
resected tissue following SRS (25) (clinicaltrials.gov; NCT03398694).  It is important 
that such studies focus on patient relevant endpoints rather than disease control.  
 7 
The use of local therapies with an option for further treatment at the time of 
development of distant intracranial disease requires more intensive surveillance of 
intracranial disease although the frequency of imaging is not clearly defined. In 
addition, the development of metastatic disease in the brain, as in other systemic 





Historically, systemic therapy was considered of limited value for brain metastases 
due to poor penetration of agents through the blood-brain barrier (BBB).  However, 
enhancing brain metastases have impaired BBB and a range of chemotherapy 
agents have shown efficacy for intracranial disease. Primary systemic therapy has 
long been considered the primary treatment of choice for patients with brain 
metastases from chemosensitive tumours such as small cell lung cancer and 
lymphoma as well as for chemonaïve chemoresponsive tumours with a significant 
chance of achieving a meaningful tumour response. Newer targeted systemic 
therapies with small (and lipid soluble) molecules have demonstrated superior 
penetration of the BBB and in some instances may deal with microscopic as well as 
macroscopic intracranial disease (26). 
 
Targeted therapy 
Targeted agents are currently the treatment of choice in advanced and disseminated 
tumours with targetable mutations such as EGFR and ALK driven non-small cell lung 
cancer (NSCLC), HER2 positive breast cancer and melanoma with BRAFV600E as 
well as MEK mutation. Although there is evidence of varying sensitivity of brain 
metastases to different tyrosine kinase inhibitors (TKIs), the efficacy in terms of 
shrinkage of brain metastases parallels systemic response rate which means that 
newer EGFR inhibitors such as Osimertinib, effective against a second mutation 
(T790M) are also more effective for CNS disease. Response rates and the duration 
of CNS disease control is improved with newer TKIs in ALK mutated tumours such 
as Alectinib and Lorlatinib when compared with Crizotinib which also parallels 
systemic efficacy (26-30). 
In general TKIs do not prevent the development of brain metastases in patients with 
microscopic (imaging undetectable) disease in the CNS with the exception of ALK 
mutated NSCLC where patients treated with second and third generation TKIs such 
as Alectinib or Lorlatinib, have lower incidence of brain metastases than following 
Crizotinib (26, 30-32). 
With improved survival of patients with HER2+ breast cancer there has been a clear 
increase in the incidence of brain metastases, and antibody and small molecule 
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therapies such as trastuzumab, trastuzumab emtansine (T-DM1) and lapatinib, have 
demonstrated intracranial activity.  Retrospective studies suggested prolonged 
survival with trastuzumab in patients with HER2+ disease with brain metastases 
(33). Retrospective subgroup analyses of larger trials suggest that second-line T-
DM1 despite its large size, is active at the time of trastuzumab resistance as well as 
in untreated patients. Newer HER2 targeted therapies show promise in heavily 
pretreated patients with intracranial response rates up to 30-40% (34). 
 
Immunotherapy 
Immunotherapy either alone or in combination with chemotherapy has become 
standard of care in many tumour types with a particular focus on melanoma, 
epithelial tumours especially NSCLC and renal cell carcinoma. Initial trials defining 
the efficacy of single agent immune checkpoint inhibitors tended to exclude patients 
with brain metastases. The apparent reduction of efficacy of immunotherapy in 
combination with corticosteroids, used frequently as symptomatic treatment for brain 
metastases also led to relatively slow introduction into the treatment of CNS disease. 
Nevertheless, where reported, brain metastases had shown shrinkage in line with 
systemic response in melanoma (35) and NSCLC (36). The possible interaction of 
radiation and immunomodulatory agents has led to initial concerns but a suggestion 
of enhanced efficacy needs further exploration (37-39).  
 
Combination of systemic therapy and radiation therapy/SRS 
Despite the efficacy of systemic therapy in the control of brain metastases the 
disease almost invariably recurs with a risk independent of status of systemic 
disease. This has led to policies of adjuvant radiotherapy either in the form of 
WBRT/partial brain RT or SRS. Retrospective studies suggest improvement in long 
term disease control in the brain although survival benefit of adjuvant radiotherapy 
(WBRT) or SRS compared to delayed treatment at the time of progression remains 
unclear and is subject to current randomised studies. Similarly adjuvant SRS may be 
of value as an additional treatment of oligometastases with suggestion of improved 
intracranial disease control in patients with targetable EGFR/ALK mutated tumours 
(40) and this too is the subject of ongoing randomised trials. Early results of SRS in 
addition to chemotherapy in patients with cerebral oligometastases at presentation of 
NSCLC (in non-mutated tumours) did not demonstrate benefit of SRS in intracranial 
tumour control or survival (41). 
The suggestion of increased efficacy of upfront combined cranial radiation with TKI 
compared to the use of TKI alone (42) is intriguing suggesting a potential future role 
for combined sequential or concomitant therapy and results of ongoing trials will help 
inform optimal sequencing (NCT03497767). 
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In patients with HER2+ breast cancer, lapatinib intracranial response rate and 
duration of tumour control is improved with the addition of SRS (43, 44).  This is 
associated with a significant risk of radionecrosis particularly when SRS is combined 
with T-DM1 and until prospective studies are completed, this combination should be 
used with caution.   
In HER2+ patients, prospective randomised trials are required for new targeted 
systemic therapies particularly when used alone. Until there is clear high-quality 
evidence to support substitution of treatments with proven efficacy, treatment with 
systemic targeted therapies without the use of radiation should be undertaken with 
caution and close monitoring. 
In patients with brain metastases and HER2 negative tumours, there is limited data 
that would allow for a change in practice from the evidence-based treatments of 
radiation (WBRT or SRS) or surgery.  
Molecular analysis of metastases at different sites including the brain suggests 
ongoing phylogenetic evolution with development of new mutations, particularly in 
breast cancer (45, 46). This may include the evolution of new targetable mutations 
as well as decline in existing targetable mutations. While the current standard is to 
offer treatment on the basis of molecular analysis of the primary tumour or 
accessible systemic metastases it may be appropriate that future strategies include 
molecular analyses of brain metastases with tissue obtained either by local sampling 
or through circulating tumour DNA (ctDNA). Whether this approach will lead to true 
widening of therapeutic options remains highly speculative.  
 
Conclusion 
Despite an ever-increasing number of management options for patients with brain 
metastases long term control remains a challenge and the choice of treatment has to 
be considered in the context of the overall disease and not as an isolated entity. 
Increasing use of more localised treatments in the form of surgery and stereotactic 
radiosurgery while more effective at achieving disease control at the treated site has 
limited impact on the overall intracranial disease control in patients with multiple 
brain metastases. Similarly the increasing use of systemic therapies for brain 
metastases, while effective in terms of tumour response rarely results in lasting 
intracranial disease control. The combination of local and systemic treatments holds 
promise though the combination requires robust evidence from tumour specific and 
ideally randomised prospective studies as combination of treatment also combines 
toxicities. The focus in assessing the effectiveness of new treatment approaches 
should shift to quality of life and survival likely to be dictated by overall disease 
control rather than intracranial tumour control alone. This also means that the current 
tendency to move the primary decision making to specialists in brain tumour 
management, be it surgeons or radiation oncologists, needs rethinking with primary 
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responsibility remaining under the control of tumour specific specialists, working 
closely with a neuro-oncology multidisciplinary team.  
The appearance of brain metastases remains an expression of disease 
dissemination with life expectancy implications and early support and involvement of 
palliative care services should be an integral part of management for a significant 
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key points  
 
1. Review of the current evidence for treatment of brain metastases particularly 
focusing on combination of treatment approaches. 
2.  Surgical resection or SRS alone remain the current treatment of choice for 
patients with small volume limited intracranial disease, good performance status and 
treatable or absent extracranial disease. 
3.  New targeted systemic therapies and immunotherapy have intracranial efficacy 
and may allow reduction or deferral of surgery, SRS and WBRT. Randomised trial 
data are awaited to inform correct sequencing and integration of systemic and local 
targeted therapies. 
4. Future trials should focus on patient relevant endpoints in the context of overall life 
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